Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients

Title	Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
Authors	Bum Jun Kim, Changhoon Yoo, Kyu-pyo Kim, Jaewon Hyung, Seong Joon Park, Baek-Yeol Ryoo, Heung-Moon Chang
Magazine	British Journal of Cancer
Date	01/12/2017
DOI	10.1038/bjc.2016.446
Introduction	This study evaluates the effectiveness of second-line fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer (BTC) following the failure of gemcitabine plus cisplatin (GEMCIS). A retrospective analysis of 321 patients who had histologically confirmed advanced BTC and received first-line GEMCIS showed that 43% received fluoropyrimidine-based second-line chemotherapy. Among these, 255 received monotherapy, and 66 received a fluoropyrimidine-platinum combination. The overall response rate (ORR) was 3%, with a disease control rate of 47%. The median progression-free survival (PFS) was 1.9 months, and overall survival (OS) was 6.5 months. While the combination therapy showed a higher ORR, it did not result in significantly different PFS or OS compared to monotherapy. The study concludes that fluoropyrimidine-based chemotherapy offers modest efficacy in advanced BTC cases after GEMCIS failure, with no significant survival advantage observed with combination therapy.
Quote	Bum Jun Kim, Changhoon Yoo and Kyu-pyo Kim et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. British Journal of Cancer. 2017. Vol. 116(5):561-567. DOI: 10.1038/bjc.2016.446
Element	Platinum (Pt)
Industry	Pharmaceutical Industry